Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary
efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in
patients with refractory malignancies principally confined to the peritoneal cavity.
Phase:
Phase 1
Details
Lead Sponsor:
CritiTech, Inc.
Collaborators:
Beckloff Associates, Inc. University of Kansas Medical Center